Data from the UALCAN and HPA databases further confirmed that PDCL3 expression was upregulated in breast invasive carcinoma (BRCA), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), ovarian cancer (OC), and pancreatic adenocarcinoma (PAAD) at the protein level (Figures 1B–M). Here, PDCL3 is linked to pancreatic adenocarcinoma.